American Heart Association Comment: Abciximab In Patients With Refractory Unstable Angina In Relation To Serum Troponin T Levels

May 27, 1999

In a scientific paper in the May 27 issue of the New England Journal of Medicine, researchers report that a drug treatment can help prevent heart attack or sudden death in a certain group of high-risk individuals who are undergoing a procedure called angioplasty to restore blood flow to an obstructed artery.

This group of individuals who have unstable angina -- severe chest pain, even at rest -- are most likely to benefit from this drug if they have high levels of troponin T, a marker for heart muscle damage.

Unstable angina, a critical condition resulting from impaired blood flow to the heart muscle, is caused by fat-laden obstructions in the heart's arteries. This condition leads to over one-half million hospitalizations a year.

This high-risk group of people who have unstable angina are sitting on a potential time bomb -- one that could suddenly transform a narrowed coronary artery into a heart attack or death.

In this study, the researchers measured participants' levels of troponin T. People with normal hearts have very low blood levels of troponin T. Troponin T levels increase substantially within several hours after an unstable angina attack and peak at 10 to 24 hours. Not all people with unstable angina have elevated troponin T levels. However, for those who do, the drug abciximab in combination with angioplasty appears to be beneficial, according to the study published in the New England Journal of Medicine.

Richard C. Pasternak, M.D., American Heart Association spokesperson and director of preventive cardiology at the Massachusetts General Hospital in Boston, Mass., says, "This study is important because it raises the possibility that even after unstable angina occurs and the bells go off, heart attack can be prevented with medical therapy."

The drug, abciximab, is a blood-thinner. It keeps blood particles known as platelets from clumping and forming clots that block blood flow, leading to a heart attack or stroke. Abciximab is one of a group of platelet blockers that are sometimes called "super aspirins" because they are more potent than regular aspirin. These "super aspirins" are given by injection into a person's vein. The study results were based on blood samples of 890 patients who were, on the average, 61 years old. They all had serious unstable angina, defined as having at least one obstructed heart artery that could be effectively treated with angioplasty.

Patients were assigned to one of two treatment groups: an injection of abciximab from 18 to 24 hours before angioplasty plus continuous infusion of abciximab into the vein until one hour after angioplasty, or a matching pre-angioplasty injection and infusion during angioplasty of an inert substance (placebo).

Six months after angioplasty, among the individuals in the high-risk, unstable angina group who had high troponin T levels and received abciximab, 9.5 percent had heart attacks or deaths, compared with 23.9 percent of the people in the untreated (placebo) high-risk, unstable angina group who had high troponin T levels.
-end-


American Heart Association

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.